3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER_GOV
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Gynecologic
1
Genitourinary
1
Conditions
Pancreatic Neoplasms
1
Colorectal Neoplasms
1
Interventions
Oxaliplatin
780
Fluorouracil
638
Capecitabine
575
Gemcitabine
478
Leucovorin
459
Bevacizumab
445
Irinotecan
444
Cisplatin
338
Radiotherapy
283
Cetuximab
252
Paclitaxel
180
S 1 (combination)
176
pembrolizumab
173
Docetaxel
156
Drug Therapy
147
Nivolumab
146
sintilimab
143
tislelizumab
131
apatinib
131
130-nm albumin-bound paclitaxel
128
Folfox protocol
121
durvalumab
119
Albumin-Bound Paclitaxel
117
camrelizumab
107
lenvatinib
106
Panitumumab
106
regorafenib
102
Surgical Procedures, Operative
102
Sorafenib
99
Radiation
88
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Etodolac
×
Gastrointestinal
×
Clear all
NCT03838029
2019-11-20
BC-PC
Assaf-Harofeh Medical Center
Phase 2
Unknown
210 enrolled
NCT03919461
2019-04-18
COMPIT-2
Assaf-Harofeh Medical Center
Phase 2
Recruiting
200 enrolled